Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
September 04, 2024 23:19 ET | Source: Robbins LLP

Robbins LLP Reminds Investors of Oddity Tech Ltd. of Upcoming Lead Plaintiff Deadline – ODD Stockholder with Significant Losses Should Contact Robbins LLP

Robbins LLP is Investigating Allegations that Oddity Tech Ltd. (ODD) Misled Investors Regarding its AI Technology and Capabilities
October 15, 2021 07:00 ET | Source: Lava Therapeutics N.V.

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and...